The Dartmouth Institute

Featured

About Us

The Dartmouth Institute (TDI) convenes researchers, educators, and practitioners from multiple disciplines across Dartmouth to work toward our mission of improving population health, reducing health disparities, and creating high-performing, sustainable health systems. We are a foundational department within the Geisel School of Medicine at Dartmouth College with deep scholarly collaborations and practice innovation partnerships with Dartmouth Health. For more than 30 years, we have been dedicated to making health and healthcare better for everyone. Our research has increased the understanding of geographic variations in healthcare delivery, the adaptation and integration of payment reform models, and the factors influencing physician decision-making and patient-clinician communication. Since 2021, we have committed to using an equity lens in our research, education, and engagement work, with the explicit goal of focusing not just on unwarranted variation but on unjust variation, in order to support clinicians, policy makers, and systems leaders to develop and implement innovative new models of healthcare delivery to advance health equity.

Learn More

Our Priorities

The Dartmouth Institute helps clinicians, policy makers, and systems leaders improve practices and develop innovative new models of healthcare delivery. TDI’s strategic plan emphasizes a healthy and inclusive workplace community, impactful research that realizes concrete health policy and healthcare delivery outcomes, and excellence in teaching for Dartmouth students who are pursuing MS, MPH, MHA, MHCDS, and PhD degrees.

RSS Recent News

  • Reflections on the White Coat September 24, 2026
    Every year, first-year medical students celebrate a rite of passage in medicine when they receive their short white coats, symbolic of their status as physicians in training. Daniela Armella Tangarife, a third-year medical student, reflects on what the white coat means to her, as Geisel prepares for the Class of 2030 White Coat Ceremony.
  • Psychedelic Therapy Is Imminent. Will the FDA Get It Right?—DoubleBlind Magazine September 21, 2026
    Read article—Amber Barnato, a professor of medicine, is featured in coverage of an FDA hearing on psychedelic therapy, urging caution as regulators consider expanded access. "I believe that FDA approval of access for terminally ill patients is ethically defensible… But ongoing comparative effectiveness research remains critical," Barnato said.